Boreal Genomics
At Boreal , we develop tools that enable non-invasive detection and monitoring of tumor mutation profiles. Today, genomic profiling of cancer is increasingly important for cancer research and development of targeted therapies. As more of these targeted therapies are developed and approved, recurrent genomic profiling of tumors will be essential for clinical research and cancer treatment. New approaches are required as current technologies for tumor mutation detection are invasive and not well suited for repeated tumor profiling. We are overcoming this challenge by developing breakthrough .... Read more
OnTarget™ is a powerful, new platform for detection of rare tumor mutations in tiss...
At Boreal, we develop tools that enable non-invasive detection and monitoring of tumor mutation profiles.
Today, genomic profiling of cancer is increasingly important for cancer research and development of targeted therapies. As more of these targeted therapies are developed and approved, recurrent genomic profiling of tumors will be essential for clinical research and cancer treatment. New approaches are required as current technologies for tumor mutation detection are invasive and not well suited for repeated tumor profiling. We are overcoming this challenge by developing breakthrough technologies for non-invasive detection of cancer mutations.
Our OnTarget™ platform, available as both an instrument or research service, allows researchers to detect customized panels of over 100 mutations from plasma or tissue.
We are a team of specialists in cancer genomics, molecular biology, engineering and physics with a passion to develop technology that impacts cancer research and treatment. We are confident that our technology will enable the first practical method for non-invasive tumor profiling. We invite you to join us in our quest to help cancer researchers and clinicians transform the detection and monitoring of cancer.
Today, genomic profiling of cancer is increasingly important for cancer research and development of targeted therapies. As more of these targeted therapies are developed and approved, recurrent genomic profiling of tumors will be essential for clinical research and cancer treatment. New approaches are required as current technologies for tumor mutation detection are invasive and not well suited for repeated tumor profiling. We are overcoming this challenge by developing breakthrough technologies for non-invasive detection of cancer mutations.
Our OnTarget™ platform, available as both an instrument or research service, allows researchers to detect customized panels of over 100 mutations from plasma or tissue.
We are a team of specialists in cancer genomics, molecular biology, engineering and physics with a passion to develop technology that impacts cancer research and treatment. We are confident that our technology will enable the first practical method for non-invasive tumor profiling. We invite you to join us in our quest to help cancer researchers and clinicians transform the detection and monitoring of cancer.